Premature Baby Nutrition Co. Nutrinia Raises $30M

August 21, 2016 | Israeli biotech startup Nutrinia has closed $30 million Series D financing to fund two pivotal trials for registration. TPG Biotech led the investment, joined by H.I.G. BioHealth Partners and WuXi Healthcare Ventures, as well as existing investors including OrbiMed, Pontifax and others. The Ramat Gan based company is developing a proprietary oral formulation of insulin for intestinal malabsorption in preterm newborns and Short Bowel Syndrome (SBS) in infants. Nutrinia will use the proceeds to initiate two pivotal trials for registration in separate indications related to acceleration of gut maturation and adaptation: intestinal malabsorption in preterm newborns born between 26 and 32 weeks’ gestational age, and infants with SBS who are under 12 months old. Nutrinia was founded by Professor Naim Shehadeh head of Pediatric Diabetes Clinic at the Rambam Medical Center in Haifa, at the NGT incubator in Nazareth, which was supported by the Jacobs family, who invested in the company’s earlier investment round along with Maabarot.